ArticleACS chemical biology2015
One-step enzymatic modification of the cell surface redirects cellular cytotoxicity and parasite tropism.
Article in ACS chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Specific Cell Targeting byCells · 2024Article
- A case for the study of native extracellular vesicles.Frontiers in oncology · 2024Article
- Proteome-Derived Peptide Libraries for Deep Specificity Profiling of N-terminal Modification Reagents.Current protocols · 2023Article
- Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles.ACS nano · 2022Article
- Lectin Drug Conjugates Targeting High Mannose N-Glycans.Chembiochem : a European journal of chemical biology · 2022Article
- Article
- Functionalized High Mannose-Specific Lectins for the Discovery of Type I Mannosidase Inhibitors.Angewandte Chemie (International ed. in English) · 2021Article
- Nongenetic Bioconjugation Strategies for Modifying Cell Membranes and Membrane Proteins: A Review.Bioconjugate chemistry · 2020Review
- 100th Anniversary of Macromolecular Science Viewpoint: Re-Engineering Cellular Interfaces with Synthetic Macromolecules Using Metabolic Glycan Labeling.ACS macro letters · 2020Article
- Engineered peptide ligases for cell signaling and bioconjugation.Biochemical Society transactions · 2020Review
- Broadening the scope of sortagging.RSC advances · 2019Review
- Natural Occurring and Engineered Enzymes for Peptide Ligation and Cyclization.Frontiers in chemistry · 2019Review
- A Single-Step Chemoenzymatic Reaction for the Construction of Antibody-Cell Conjugates.ACS central science · 2018Article
- Programming Cell-Cell Interactions through Non-genetic Membrane Engineering.Cell chemical biology · 2018Review
- Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic labelling.Nature · 2018Article
- Cell surface engineering and application in cell delivery to heart diseases.Journal of biological engineering · 2018Review
- The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent.Scientific reports · 2017Article
- Site-Specific Protein Labeling via Sortase-Mediated Transpeptidation.Current protocols in protein science · 2017Article
- On-demand dissolution of modular, synthetic extracellular matrix reveals local epithelial-stromal communication networks.Biomaterials · 2017Article
- Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Surface display of engineered proteins has many useful applications. The expression of a synthetic chimeric antigen receptor composed of an extracellular tumor-specific antibody fragment linked to a cytosolic activating motif in engineered T cells is now considered a viable approach for the treatment of leukemias. The risk of de novo tumor development, inherent in the transfer of genetically engineered cells, calls for alternative approaches for the functionalization of the lymphocyte plasma membrane. We demonstrate the conjugation of LPXTG-tagged probes and LPXTG-bearing proteins to endogenous acceptors at the plasma membrane in a single step using sortase A. We successfully conjugated biotin probes not only to mouse hematopoietic cells but also to yeast cells, 293T cells, and Toxoplasma gondii. Installation of single domain antibodies on activated CD8 T cell redirects cell-specific cytotoxicity to cells that bear the relevant antigen. Likewise, conjugation of Toxoplasma gondii with single domain antibodies targets the pathogen to cells that express the antigen recognized by these single domain antibodies. This simple and robust enzymatic approach enables engineering of the plasma membrane for research or therapy under physiological reaction conditions that ensure the viability of the modified cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.